Q-omics provides the consensus-scored ZNF22 profile across patient tissues and cancer cell-line models. ZNF22 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ZNF22 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, ZNF22 RNA expression shows 19,351 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, KICH, and UVM as cancer lineages where ZNF22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF22 survival associations across molecular data types. ZNF22 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF22 RNA expression–survival associations across cancer types. High ZNF22 expression shows unfavorable associations in STAD, SCLC and UVM, but favorable associations in KIRC, GBM and LUAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for ZNF22 RNA expression.
This table summarizes ZNF22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF22 shows lower tumor expression in KICH, THCA and LUAD and higher tumor expression in KIRC, HNSC and STAD. The KICH box plot shows higher ZNF22 RNA expression in normal versus tumor tissue (log2 FC = −1.940, t-test p < 0.001).
This table shows molecular features associated with ZNF22 in patient tissues and cancer cell lines. In patient samples, ZNF22 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUSC.
